MDM2 and glioblastoma: In this respect, while agents inhibiting either the AKT/mTOR pathway13, 14, 15 or the MDM2/p53 interaction16, 17, 18 have provided some survival benefit in GBM, the effects of a co-therapy have not been deeply investigated to date, either in GBMs or in their stem cells.